New drugs for pain management in advanced cancer patients

References

• Van Den Beuken-Van Everdingen MH, Hochstenbach LM, Joosten EA, et al. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage. 2016;51:1070–1090.
   PubMed Web of Science ®Google Scholar
• Mercadante S. Cancer pain. Curr Opin Support Palliat Care. 2013;7:139–143.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Portenoy RK. Breakthrough cancer pain: twenty-five years of study. Pain. 2016;157:2657–2663.
   PubMed Web of Science ®Google Scholar
• Caraceni A, Hanks G, Kaasa S, et al. European Palliative Care Research Collaborative (EPCRC).; European Association for Palliative Care (EAPC).Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58–68.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Bruera E. Opioid switching in cancer pain: from the beginning to nowadays. Crit Rev Oncol Hematol. 2016;99:241–248.
   PubMed Web of Science ®Google Scholar
• Koyyalagunta D, Bruera E, Solanki DR, et al. A systematic review of randomized trials on the effectiveness of opioids for cancer pain. Pain Physician. 2012;15(3 Suppl):ES39–58.
   PubMed Web of Science ®Google Scholar
• Mercadante S. Why are our patients still suffering? Nat Clin Prac Oncol. 2007;4:138–139.
   PubMedGoogle Scholar
• Chapman CR, Lipschitz DL, Angst MS, et al. Opioid pharmacotherapy for chronic noncancer pain in the united states: a research guideline for developing an evidence-base. J Pain. 2010;11:807–829.
   PubMed Web of Science ®Google Scholar
• Mercadante S. Opioid metabolism and clinical aspects. Eur J Pharmacol. 2015;769:71–78.
   PubMed Web of Science ®Google Scholar
• Cherny NI, Baselga J, De Conno F, et al. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC opioid policy initiative. Ann Oncol. 2009;21:615–626.
   Web of Science ®Google Scholar
• Zogenix. Zogenix Website Zohydro ER Information page. Available from: http://www.zogenix.com/content/pipeline/zohydro.htm.
   Google Scholar
• Egalet Ltd. Egalet Ltd- Tamper Resistance. Available from: http://www.egalet.com/technology/technology-overview/tamperresistance/. Accessed December 4, 2012.
   Google Scholar
• De Leon J, Dinsmore L, Wedlund P. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. Clin Psychopharm. 2003;23:420–421.
   PubMed Web of Science ®Google Scholar
• Rodriguez RF, Castillo JM, Castillo MP, et al. Hydrocodone/acetaminophen and tramadol chlorhydrate combination tablets for the management of chronic cancer pain: a double-blind comparative trial. Clin J Pain. 2008;24:1–4.
   PubMed Web of Science ®Google Scholar
• Rodriguez RF, Bravo LE, Castro F, et al. Incidence of weak opioids adverse events in the management of cancer pain: a double-blind comparative trial. J Palliat Med. 2007;10:56–60.
   PubMed Web of Science ®Google Scholar
• Ho T, Vrabec JT, Burton AW. Hydrocodone use and sensorineural hearing loss. Pain Phys. 2007;10:467–472.
   PubMedGoogle Scholar
• Sloan P. Review of oral oxymorphone in the management of pain. Ther Clin Risk Manage. 2008;4:777–787.
   PubMedGoogle Scholar
• Sloan P, Slatkin N, Ahdieh H. Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. Support Care Cancer. 2005;13:57–65.
   PubMed Web of Science ®Google Scholar
• Slatkin NE, Rhiner MI, Gould EM, et al. Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer. J Opioid Manage. 2010;6:181–191.
   PubMedGoogle Scholar
• Gabrail NY, Dvergsten C, Ahdieh H. Establishing the dosage equivalency of oxymorphone extended-release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr Med Res Opin. 2004;20:911–918.
   PubMed Web of Science ®Google Scholar
• Mayyas F, Fayers P, Kaasa S, et al. A systematic review of oxymorphone in the management of chronic pain. J Pain Symptom Manage. 2010;39:296–308.
   PubMed Web of Science ®Google Scholar
• Kress HG, Koch ED, Kosturski H, et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician. 2014;17:329–343.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Porzio G, Gebbia V. New opioids. J Clin Oncol. 2014;32:1671–1676.
   PubMed Web of Science ®Google Scholar
• Baron R, Eberhart L, Kern KU, et al. Tapentadol Prolonged release for chronic pain: a review of clinical trials and 5 years of routine clinical practice data. Pain Pract. 2016 Sep 9. DOI:10.1111/papr.12515.
   Google Scholar
• Barbosa J, Faria J, Queirós O, et al. Comparative metabolism of tramadol and tapentadol: a toxicological perspective. Drug Metab Rev. 2016;48:577–592.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Porzio G, Ferrera P, et al. Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin. 2012;28:1775–1779.
   PubMed Web of Science ®Google Scholar
• Kress HG, Koch ED, Kosturski H, et al. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. Eur J Pain. 2016;20:1513–1518.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Porzio G, Aielli F, et al. Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. Curr Med Res Opin. 2013;29:661–666.
   PubMed Web of Science ®Google Scholar
• Mercadante S. Prospects and challenges in opioid analgesia for pain management. Curr Med Res Opin. 2011;27:1741–1743.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Giarratano A. Combined oral prolonged-release oxycodone and naloxone in chronic pain management. Expert Opin Investig Drugs. 2013;22:161–166.
   PubMed Web of Science ®Google Scholar
• Ahmedzai SH, Nauck F, Bar-Sela G, et al. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Pall Med. 2012;26:50–60.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Ferrera P, David F, et al. The use of high doses of oxycodone in an acute palliative care unit. Am J Hosp Palliat Care. 2011;28:242–244.
   PubMed Web of Science ®Google Scholar
• Leppert W, Woron J. The role of naloxegol in the management of opioid-induced bowel dysfunction. Therap Adv Gastroenterol. 2016;9:736–746.
   PubMed Web of Science ®Google Scholar
• Argoff CE, Kopecky EA. Patients with chronic pain and dysphagia (CPD): unmet medical needs and pharmacologic treatment options. Curr Med Res Opin. 2014;30:2543–2559.
   PubMed Web of Science ®Google Scholar
• Fleming AB, Carlson DR, Varanasi RK, et al. Evaluation of an extended-release, abuse-deterrent, microsphere-in-capsule analgesic for the management of patients with Chronic Pain With Dysphagia (CPD). Pain Pract. 2016;16:334–344.
   PubMed Web of Science ®Google Scholar
• Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs. 2012;72:181–190.
   PubMed Web of Science ®Google Scholar
• Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manage. 2013;46:573–580.
   PubMed Web of Science ®Google Scholar
• Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Oncol Hematol. 2011;80:460–465.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Gatti A, Porzio G, et al. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional. Curr Med Res Opin. 2012;28:963–968.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Craig D, Giarratano A. US food and drug administration’s risk evaluation and mitigation strategy for extended-release and long-acting opioids: pros and cons, and a European perspective. Drugs. 2012;72:2327–2332.
   PubMed Web of Science ®Google Scholar
• Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84:613–624.
   PubMed Web of Science ®Google Scholar
• Mercadante S, Porzio G, Adile C, et al. Pain intensity as prognostic factor in cancer pain management. Pain Pract. 2015;15:E1–8.
   PubMed Web of Science ®Google Scholar